Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Monte Rosa Therapeutics announced Novartis initiated a second Phase 2 study of the VAV1-directed molecular glue degrader MRT-6160 (DDY391), this one in active moderate to severe psoriatic arthritis. The first patient visit triggers a $37.5 million milestone payment to Monte Rosa under the global exclusive license agreement, which carries up to $2.1 billion in total milestones. Novartis funds and conducts Phase 2 development; Monte Rosa co-funds any Phase 3, shares 30% of U.S. profit/loss, and earns tiered ex-U.S.
Key figures
- Deal Value Usd
- $2.1 billion
- Us profit share
- 30%
- Study identifier
- NCT07801495
- Milestone payment usd
- 37500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.